Desyrel (trazodone) increases risk of diabetes 116%

Posted by .(JavaScript must be enabled to view this email address)
Tuesday, April 05, 2011 6:17 am Email this article
The antidepressant Desyrel or Oleptro (trazodone) increases the risk of diabetes 116% -- or 2.2-fold -- according to an analysis by researchers from Charité University Medical Center in Berlin, Germany.

Note: This was not statistically significant, but it was close enough that I consider it irrelevant. Based on the numbers, it appears that there was perhaps a 7-8% chance of this difference being due to random chance, which means that there was probably a 92-93% chance that the increased risk of diabetes was due to the drug. Therefore, I consider it irrelevant. To me, statistical significance is often misused to try and convince both doctors and the public that a link does not exist, but it is overwhelming likely that this increased risk of diabetes was due to the drug and not due to random chance.

Those who had taken the drug for 2 years or more

Those who had taken the drug for 2 years or more versus those who had not taken an antidepressant in the previous two years

The study compared the risk of diabetes in people who had taken antidepressants for 2 years or more compared to those had not taken an antidepressants during the previous two years.

 

Subjects

Subjects: 165,958 patients

The analysis looked at “165,958 patients with depression who received at least one new prescription for an antidepressant between January 1, 1990, and June 30, 2005”.

 

Conclusion

Conclusion: Long-term use of antidepressants increases risk of diabetes

“Long-term use of antidepressants in at least moderate daily doses was associated with an increased risk of diabetes. This association was observed for both tricyclic antidepressants and selective serotonin reuptake inhibitors,” the researchers concluded.

REFERENCE

Andersohn F, Schade R, Suissa S, Garbe E. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry. 2009 May, 166(5):591-98.

AUTHOR’S CONTACT INFORMATION

Frank Andersohn, MD
Bremen Institute for Prevention Research and Social Medicine
Epidemiology, and Health Economics
Charité University Medical Center
10098 Berlin, Germany
.(JavaScript must be enabled to view this email address)

Articles on the same subject can be found here:

• Diabetes